EE200300437A - Triasolopüridiinid kui põletikuvastased ained - Google Patents

Triasolopüridiinid kui põletikuvastased ained

Info

Publication number
EE200300437A
EE200300437A EEP200300437A EEP200300437A EE200300437A EE 200300437 A EE200300437 A EE 200300437A EE P200300437 A EEP200300437 A EE P200300437A EE P200300437 A EEP200300437 A EE P200300437A EE 200300437 A EE200300437 A EE 200300437A
Authority
EE
Estonia
Prior art keywords
triazolopyridines
inflammatory agents
inflammatory
agents
Prior art date
Application number
EEP200300437A
Other languages
English (en)
Estonian (et)
Inventor
Anthony Dombroski Mark
Jacob Duplantier Allen
Ruth Laird Ellen
Anthony Letavic Michael
Francis Mcclure Kim
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of EE200300437A publication Critical patent/EE200300437A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EEP200300437A 2001-03-09 2002-02-08 Triasolopüridiinid kui põletikuvastased ained EE200300437A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27484001P 2001-03-09 2001-03-09
PCT/IB2002/000424 WO2002072579A1 (en) 2001-03-09 2002-02-08 Triazolopyridines as anti-inflammatory agents

Publications (1)

Publication Number Publication Date
EE200300437A true EE200300437A (et) 2004-02-16

Family

ID=23049813

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300437A EE200300437A (et) 2001-03-09 2002-02-08 Triasolopüridiinid kui põletikuvastased ained

Country Status (37)

Country Link
US (1) US6696464B2 (xx)
EP (1) EP1370559B1 (xx)
JP (1) JP4130774B2 (xx)
KR (1) KR20030080087A (xx)
CN (1) CN1496366A (xx)
AP (1) AP2002002463A0 (xx)
AR (1) AR036152A1 (xx)
AT (1) ATE323701T1 (xx)
BG (1) BG108133A (xx)
BR (1) BR0207990A (xx)
CA (1) CA2440222C (xx)
CR (1) CR7013A (xx)
CZ (1) CZ20032185A3 (xx)
DE (1) DE60210755T2 (xx)
DO (1) DOP2002000353A (xx)
EA (1) EA200300864A1 (xx)
EC (1) ECSP034762A (xx)
EE (1) EE200300437A (xx)
ES (1) ES2260415T3 (xx)
GT (1) GT200200042A (xx)
HR (1) HRP20030719A2 (xx)
HU (1) HUP0303415A2 (xx)
IL (1) IL156567A0 (xx)
IS (1) IS6858A (xx)
MA (1) MA26991A1 (xx)
MX (1) MXPA03008144A (xx)
NO (1) NO20033969L (xx)
NZ (1) NZ526528A (xx)
OA (1) OA12552A (xx)
PA (1) PA8541001A1 (xx)
PE (1) PE20030010A1 (xx)
PL (1) PL363959A1 (xx)
SK (1) SK10272003A3 (xx)
TN (1) TNSN02022A1 (xx)
UY (1) UY27199A1 (xx)
WO (1) WO2002072579A1 (xx)
ZA (1) ZA200304983B (xx)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372206B1 (en) * 1989-03-02 2002-04-16 University Of Florida Orally-administered interferon-TAU compositions and methods
US20040077605A1 (en) * 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
EP1854798A3 (en) * 2000-09-19 2007-11-28 Bristol-Myers Squibb Company Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US20040087548A1 (en) 2001-02-27 2004-05-06 Salvati Mark E. Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
GB0124933D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124941D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124931D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124939D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124934D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124938D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124936D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
AU2002364082A1 (en) * 2001-12-19 2003-07-09 Bristol-Myers Squibb Company Fused heterocyclic compounds and analogs thereof: modulators of nuclear hormone receptor function
ATE375980T1 (de) 2002-02-12 2007-11-15 Smithkline Beecham Corp Nicotinamide und deren verwendung als p38 inhibitoren
GB0217757D0 (en) 2002-07-31 2002-09-11 Glaxo Group Ltd Novel compounds
PA8579601A1 (es) 2002-08-30 2004-05-07 Pfizer Prod Inc Compuestos antiinflamatorios de di y trifloruro-triazolo-piridinas
US6949652B2 (en) 2002-08-30 2005-09-27 Pfizer, Inc. Crystalline forms of 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo-[4,3-A]pyridine
CA2496812A1 (en) * 2002-08-30 2004-03-11 Pfizer Products Inc. Novel processes and intermediates for preparing triazolo-pyridines
US20040092547A1 (en) * 2002-08-30 2004-05-13 Pfizer Inc Alkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines
US7037923B2 (en) 2002-08-30 2006-05-02 Pfizer, Inc. Alkyl-[4-(trifluorophenyl)-oxazol-5-yl]-triazolo-pyridines
US7005523B2 (en) 2002-08-30 2006-02-28 Pfizer Inc. Cycloalkyl-[4-(trifluorophenyl)-oxazol-5yl]-triazolo-pyridines
US7012143B2 (en) 2002-08-30 2006-03-14 Dombroski Mark A Cycloalkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines
CA2515190A1 (en) * 2003-02-14 2004-08-26 Pfizer Products Inc. Triazolo-pyridines as anti-inflammatory compounds
US7521447B2 (en) 2003-03-03 2009-04-21 Array Biopharma Inc. P38 inhibitors and methods of use thereof
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
PA8595001A1 (es) * 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
GB0308201D0 (en) * 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0308186D0 (en) * 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0308185D0 (en) * 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
BRPI0417674A (pt) * 2003-12-18 2007-03-20 Pfizer Prod Inc método para tratar a inflamação aguda em animais, com inibidores de quinase map p38
GB0402143D0 (en) * 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
TWI332003B (en) 2004-01-30 2010-10-21 Lilly Co Eli Kinase inhibitors
AU2005260031B2 (en) * 2004-06-25 2008-10-09 Amgen Inc. Condensed triazoles and indazoles useful in treating citokines mediated diseases and other diseases
KR100871535B1 (ko) 2004-08-12 2008-12-05 화이자 인코포레이티드 Ｐ38 ｍａｐ 키나아제 억제제로서의트리아졸로피리딘일설판일 유도체
ES2314690T3 (es) * 2004-08-12 2009-03-16 Pfizer, Inc. Derivados de triazolopiridinilsulfanilo como inhibidores de la map quinasa p38.
MX2007001612A (es) * 2004-08-18 2007-04-10 Upjohn Co Compuestos novedosos de triazolopiridina para el tratamiento de la inflamacion.
CA2577478A1 (en) * 2004-08-18 2006-02-23 Pharmacia & Upjohn Company Llc Triazolopyridine compounds
US20080051416A1 (en) * 2004-10-05 2008-02-28 Smithkline Beecham Corporation Novel Compounds
US7579360B2 (en) * 2005-06-09 2009-08-25 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
US7572807B2 (en) * 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
GB0512429D0 (en) * 2005-06-17 2005-07-27 Smithkline Beecham Corp Novel compound
PE20070404A1 (es) * 2005-07-29 2007-05-10 Wyeth Corp Compuestos derivados de cianopirrol-sulfonamida como moduladores del receptor de progesterona
PE20070341A1 (es) * 2005-07-29 2007-04-13 Wyeth Corp Derivados de pirrol como moduladores del receptor de progesterona
PE20070182A1 (es) 2005-07-29 2007-03-06 Wyeth Corp Derivados cianopirrol-fenil amida como moduladores del receptor de progesterona
EP1981851B1 (en) 2006-01-31 2012-01-25 Array Biopharma, Inc. Kinase inhibitors and methods of use thereof
WO2008021781A1 (en) 2006-08-07 2008-02-21 Incyte Corporation Triazolotriazines as kinase inhibitors
ES2301380B1 (es) 2006-08-09 2009-06-08 Laboratorios Almirall S.A. Nuevos derivados de 1,7-naftiridina.
EP2068869A4 (en) 2006-10-06 2011-05-25 Abbott Lab NEW IMIDAZOTHIAZOLE AND IMIDAZOXAZOLE
EP3443958A1 (en) 2006-11-22 2019-02-20 Incyte Holdings Corporation Imidazotriazines and imidazopyrimidines as kinase inhibitors
ES2320955B1 (es) 2007-03-02 2010-03-16 Laboratorios Almirall S.A. Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida.
ES2329639B1 (es) 2007-04-26 2010-09-23 Laboratorios Almirall S.A. Nuevos derivados de 4,8-difenilpoliazanaftaleno.
US8188083B2 (en) * 2007-06-28 2012-05-29 Abbott Laboratories Triazolopyridazines
CN101878212A (zh) * 2007-08-31 2010-11-03 默克雪兰诺有限公司 三唑并吡啶化合物及其作为ask抑制剂的用途
US8119658B2 (en) 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
EP2108641A1 (en) 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
EP2113503A1 (en) 2008-04-28 2009-11-04 Laboratorios Almirall, S.A. New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors
PL2300455T3 (pl) 2008-05-21 2018-02-28 Incyte Holdings Corporation Sole 2-fluoro-N-metylo-4-[7-(chinolin-6-ylometylo)imidazo[1,2-b][1, 2,4)triazyn-2-ylo)benzamidu i procesy związane z ich wytworzeniem
US8895550B2 (en) 2008-08-19 2014-11-25 Array Biopharma Inc. Triazolopyridine compounds as PIM kinase inhibitors
TWI496779B (zh) 2008-08-19 2015-08-21 Array Biopharma Inc 作為ｐｉｍ激酶抑制劑之三唑吡啶化合物
US8987251B2 (en) 2008-08-19 2015-03-24 Array Biopharma Inc. Triazolopyridine compounds as PIM kinase inhibitors
US8557809B2 (en) 2008-08-19 2013-10-15 Array Biopharma Inc. Triazolopyridine compounds as PIM kinase inhibitors
ES2642586T3 (es) 2009-07-27 2017-11-16 Gilead Sciences, Inc. Compuestos heterocíclicos condensados como moduladores de canales iónicos
EP2322176A1 (en) 2009-11-11 2011-05-18 Almirall, S.A. New 7-phenyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives
JP5714030B2 (ja) 2010-02-03 2015-05-07 インサイト コーポレーションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Ｃ−Ｍｅｔ阻害剤としてのイミダゾ［１，２−ｂ］［１，２，４］トリアジン
BR112012033402A2 (pt) 2010-07-02 2017-01-24 Gilead Sciences Inc moduladores de canais de íons conforme os compostos heterocíclicos fundidos
WO2012065297A1 (en) * 2010-11-16 2012-05-24 Impact Therapeutics, Inc. 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF
CN103370316B (zh) * 2010-11-16 2015-06-24 南京英派药业有限公司 作为细胞增殖抑制剂的3-芳基-6-芳基-[1,2,4]三唑并[4,3-a]吡啶及其应用
US8889704B2 (en) 2011-02-25 2014-11-18 Array Biopharma Inc. Triazolopyridine compounds as PIM kinase inhibitors
US9115096B2 (en) 2011-05-10 2015-08-25 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
NO3175985T3 (xx) 2011-07-01 2018-04-28
TWI478908B (zh) 2011-07-01 2015-04-01 Gilead Sciences Inc 作為離子通道調節劑之稠合雜環化合物
US9550775B2 (en) * 2013-03-14 2017-01-24 Genentech, Inc. Substituted triazolopyridines and methods of use thereof
GB201321742D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
WO2015157955A1 (en) * 2014-04-17 2015-10-22 Abbvie Inc. Heterocyclic btk inhibit ors
GB201511382D0 (en) 2015-06-29 2015-08-12 Imp Innovations Ltd Novel compounds and their use in therapy
WO2017151409A1 (en) 2016-02-29 2017-09-08 University Of Florida Research Foundation, Incorporated Chemotherapeutic methods
SG11202003035SA (en) 2017-10-05 2020-04-29 Fulcrum Therapeutics Inc Use of p38 inhibitors to reduce expression of dux4
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CN116514801A (zh) * 2022-01-20 2023-08-01 四川大学 2-苯基-[1,2,4]三唑并[1,5-a]吡啶类化合物、其氮氧化物及用途
CN114504636B (zh) * 2022-01-27 2023-09-26 华南理工大学 一种杏仁油烫伤膏及其制备方法与应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US576499A (en) * 1897-02-02 Gas apparatus
US5716972A (en) * 1993-01-13 1998-02-10 Smithkline Beecham Corporation Pyridyl substituted imidazoles
JP3377529B2 (ja) 1993-09-17 2003-02-17 スミスクライン・ビーチャム・コーポレイション 薬物結合タンパク質
IT1269176B (it) * 1994-01-11 1997-03-21 Isagro Srl Eterobicicli ad attivita' fungicida
US5717100A (en) 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
WO1997025045A1 (en) 1996-01-11 1997-07-17 Smithkline Beecham Corporation Novel substituted imidazole compounds
ZA97175B (en) * 1996-01-11 1997-11-04 Smithkline Beecham Corp Novel substituted imidazole compounds.
GB9713726D0 (en) 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds
JP2002516325A (ja) 1998-05-26 2002-06-04 スミスクライン・ビーチャム・コーポレイション 新規な置換イミダゾール化合物
US6207687B1 (en) * 1998-07-31 2001-03-27 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
US6350744B1 (en) 1998-11-20 2002-02-26 Merck & Co., Inc. Compounds having cytokine inhibitory activity
DK1140916T3 (da) 1998-12-16 2003-03-10 Aventis Pharma Ltd Heteroaryl-cykliske acetaler
EP1140083A4 (en) 1999-01-08 2004-01-02 Smithkline Beecham Corp NEW CONNECTIONS
EP1158985B1 (en) 1999-01-13 2011-12-28 Bayer HealthCare LLC OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
CO5170501A1 (es) 1999-04-14 2002-06-27 Novartis Ag AZOLES SUSTITUIDOS UTILES PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR TNFa eIL-1 Y ENFERMEDADES DEL METABOLISMO OSEO

Also Published As

Publication number Publication date
CA2440222A1 (en) 2002-09-19
ATE323701T1 (de) 2006-05-15
IS6858A (is) 2003-06-23
PE20030010A1 (es) 2003-01-29
OA12552A (en) 2006-06-06
DE60210755T2 (de) 2006-11-16
TNSN02022A1 (fr) 2005-12-23
JP4130774B2 (ja) 2008-08-06
GT200200042A (es) 2003-02-11
KR20030080087A (ko) 2003-10-10
NZ526528A (en) 2005-02-25
CR7013A (es) 2003-11-25
JP2004522799A (ja) 2004-07-29
EP1370559A1 (en) 2003-12-17
SK10272003A3 (sk) 2004-07-07
EA200300864A1 (ru) 2003-12-25
CA2440222C (en) 2008-11-18
PL363959A1 (en) 2004-11-29
UY27199A1 (es) 2002-10-31
BG108133A (bg) 2004-09-30
CZ20032185A3 (en) 2004-06-16
PA8541001A1 (es) 2003-05-14
BR0207990A (pt) 2004-04-27
US6696464B2 (en) 2004-02-24
MXPA03008144A (es) 2003-12-12
AP2002002463A0 (en) 2002-06-30
MA26991A1 (fr) 2004-12-20
ECSP034762A (es) 2003-10-28
WO2002072579A1 (en) 2002-09-19
EP1370559B1 (en) 2006-04-19
NO20033969D0 (no) 2003-09-08
IL156567A0 (en) 2004-01-04
HUP0303415A2 (hu) 2004-01-28
ZA200304983B (en) 2004-06-29
ES2260415T3 (es) 2006-11-01
AR036152A1 (es) 2004-08-18
US20030096838A1 (en) 2003-05-22
DOP2002000353A (es) 2002-10-15
DE60210755D1 (de) 2006-05-24
NO20033969L (no) 2003-10-13
HRP20030719A2 (en) 2005-04-30
CN1496366A (zh) 2004-05-12

Similar Documents

Publication Publication Date Title
EE200300437A (et) Triasolopüridiinid kui põletikuvastased ained
EE200300043A (et) Mittesteroidsed põletikuvastased ained
ATE285675T1 (de) Zaun
NO20042755L (no) Amidsubstituerte imidazopyridiner
NO20035476D0 (no) Azaindoler
EE200400075A (et) Peroraalsed antidiabeetilised ained
NO20033205D0 (no) Terapeutiske kromanforbindelser
EE200400004A (et) Oksasolidinoonide derivaadid kui antibakteriaalsed ained
DE60229764D1 (de) Entgratwerkzeug
IS7159A (is) Ný imídasópýridínefnasambönd sem hafa meðferðarfræðileg áhrif
DK1691814T3 (da) Antiinflammatoriske midler
DE50212755D1 (de) Bohrfutter
ES1049596Y (es) Anillo perfeccionado
ES1048896Y (es) Escalera perfeccionada
NO20012585L (no) Hylsemutter
ES1049510Y (es) Colgador-retenedor perfeccionado
ES1049544Y (es) Macetero perfeccionado
ES1050664Y (es) Sacacorchos perfeccionado
ES1048641Y (es) Troquel perfeccionado
SE0103854D0 (sv) Therapeutic agents
SE0103855D0 (sv) Therapeutic agents
NO20011527D0 (no) Spann
ES1050344Y (es) Parasol perfeccionado
ES1050272Y (es) Parasol perfeccionado
FI5386U1 (fi) Jyrsin